2022 Inflammatory Episode → 2025 AML: A Clonal Evolution Narrative?

Source Documents

Ordering provider: Sudheendra Ghosh

The 2022 Episode: Key Values

Sept 20 (peak):
- CRP 128.13 mg/L (H — massively elevated, ref <6)
- ESR 119 mm/hr (H)
- WBC 14,770 (H — leukocytosis)
- IgE 203.1 IU/mL (H — allergic/parasitic component)
- D-Dimer 0.48 ug/mL (normal — no thrombosis)

Sept 27 (resolving):
- CRP 4.89 mg/L (normalized)
- ESR 62 mm/hr (still elevated but halved)
- WBC 9,550 (normalized)
- IgE 134.4 IU/mL (still elevated)
- Platelets 501,000 (H — reactive thrombocytosis)
- Hemoglobin 11.0 g/dL (L — mild anemia)
- MCV 87.5 fL (normocytic — pre-AML baseline)

See also: Crp, Esr, Wbc, Total Ige, D Dimer, Platelet Count, Hemoglobin, Mcv

The 2025 Presentation: Contrast

By November 2025, the picture had inverted:
- WBC 2,320 (pancytopenia, not leukocytosis)
- Platelets 60,000–80,000 (thrombocytopenia, not thrombocytosis)
- Hemoglobin 8.3 g/dL (worsening anemia)
- ANC 1,090 (neutropenia)

See: Aml, Pancytopenia, Anemia

The Hypothesis: Phenotype Shift from Proliferative to Failure

MDS-related AML (with mutations in RUNX1, ASXL1, BCOR, SRSF2, STAG2) often develops over years from clonal hematopoiesis of indeterminate potential (CHIP). The hypothesis:

1. 2022: A dysplastic clone was already present, manifesting as an exaggerated inflammatory response — the marrow was proliferative but disordered. The elevated WBC (14,770), reactive thrombocytosis (501K), and mild anemia (11.0) are consistent with a proliferative phenotype of early clonal disease.

2. 2022–2025 (silent interval): The clone accumulated additional mutations or shifted its biology. No lab monitoring during this ~3-year gap.

3. 2025: The clone had progressed to overt AML with bone marrow failure — pancytopenia, circulating blasts, and a hypocellular-then-normocellular marrow packed with dysplastic cells. The failure phenotype had replaced the earlier proliferative one.

This connection is hypothesis-level. The 2022 episode was never formally diagnosed, and no bone marrow biopsy or molecular testing was performed in 2022. The causal link between 2022 inflammation and 2025 AML cannot be proven retrospectively.

What Was the 2022 Episode?

The etiology remains undiagnosed. Differential at the time would have included:
- Infection (most common cause of this pattern — but no diagnosis documented)
- Autoimmune flare (ANA was later positive in 2025, though at low titer)
- Allergic/parasitic (IgE 203 supports this component)
- Early clonal hematopoiesis with inflammatory phenotype (the retrospective hypothesis)

The rapid resolution (CRP 128→4.89 in 7 days) argues for an acute trigger (infection or allergic) rather than a purely clonal process. However, these are not mutually exclusive — a dysplastic clone may produce an exaggerated response to an ordinary trigger.

The 3-Year Gap

No laboratory data exists between September 2022 and July 2025 (pre-AML metabolic baseline at Devi Scans). This is a critical data gap — any transitional hematologic changes during 2023–2024 are unknown.

Cross-References

• Crp — CRP trend (128 → 32.7 → 4.89 → normalized)
• Esr — ESR trend (119 → 62 → 42 in Nov 2025)
• Wbc — WBC trajectory: 14,770 (2022) → 2,320 (Nov 2025) → recovering on Aza-Ven
• Platelet Count — Platelets: 501K (2022 reactive) → 60K (2025 failure) → 140K (recovering)
• Hemoglobin — Hb: 11.0 (2022 mild) → 6.8 (2025 nadir) → 10.5 (recovering)
• Mcv — MCV: 87.5 fL (2022, normocytic) → 95+ (2025, macrocytic) — MDS-associated shift
• Aml — Full AML clinical narrative
• Counter Intuitive Insights — Insight #4: "2022 episode as early MDS signal"